Poly(ADP-ribose) polymerase-1 activation in a primate model of multiple sclerosis

Journal of Neuroscience Research

Volumn 81, Issue 2, 2005, Pages 190-198

  Kauppinen, Tiina M ^a   Suh, Sang Won ^a   Genain, Claude P ^b   Swanson, Raymond A ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Astrocyte; Experimental allergic encephalomyelitis; Microglia, oligodendrocyte

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BLOOD CELL; CONTROLLED STUDY; DEMYELINATION; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; MICROGLIA; MULTIPLE SCLEROSIS; NERVE CELL; NONHUMAN; OLIGODENDROGLIA; PRIMATE; PRIORITY JOURNAL; RECURRENT DISEASE;

ANIMALS; CALLITHRIX; DEMYELINATING DISEASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME ACTIVATION; MICROGLIA; MULTIPLE SCLEROSIS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 23844531504     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20525     Document Type: Article

References (54)

1. + depletion and mitochondrial permeability transition. J Biol Chem 279:18895-18902.
2. Ame JC, Spenlehauer C, de Murcia G. 2004. The PARP superfamily. Bioessays 26:882-893.
3. Berger NA. 1985. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res 101:4-15.
4. Besler HT, Comoglu S. 2003. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr Neurosci 6:189-196.
5. Besson VC, Margaill I, Plotkine M, Marchand-Verrecchia C. 2003. Deleterious activation of poly(ADP-ribose)polymerase-1 in brain after in vivo oxidative stress. Free Radic Res 37:1201-1208.
6. Brenner T, Brocke S, Szafer F, Sobel RA, Parkinson JF, Perez DH, Steinman L. 1997. Inhibition of nitric oxide synthase for treatment of experimental autoimmune encephalomyelitis. J Immunol 158:2940-2946.
7. Calabrese V, Bella R, Testa D, Spadaro F, Scrofani A, Rizza V, Pennisi G. 1998. Increased cerebrospinal fluid and plasma levels of ultraweak chemiluminescence are associated with changes in the thiol pool and lipid-soluble fluorescence in multiple sclerosis: the pathogenic role of oxidative stress. Drugs Exp Clin Res 24:125-131.
8. Chiarugi A. 2002. Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats. Br J Pharmacol 137:761-770.
9. Chiarugi A, Moskowitz MA. 2003. Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J Neurochem 85:306-317.
10. Cohen-Armon M, Visochek L, Katzoff A, Levitan D, Susswein AJ, Klein R, Valbrun M, Schwartz JH. 2004. Long-term memory requires poly-ADP-ribosylation. Science 304:1820-1822.
11. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. 1999. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 342:249-268.
12. Davidovic L, Vodenicharov M, Affar EB, Poirier GG. 2001. Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism. Exp Cell Res 268:7-13.
13. Diestel A, Aktas O, Hackel D, Hake I, Meier S, Raine CS, Nitsch R, Zipp F, Ullrich O. 2003. Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage. J Exp Med 198:1729-1740.
14. Endres M, Wang ZQ, Namura S, Waeber C, Moskowitz MA. 1997. Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase. J Cereb Blood Flow Metab 17:1143-1151.
15. Genain CP, Hauser SL. 1996. Allergic encephalomyelitis in common marmosets: pathogenesis of a multiple sclerosis-like lesion. Methods 10:420-434.
16. Genain CP, Hauser SL. 2001. Experimental allergic encephalomyelitis in the New World monkey Callithrix jacchus. Immunol Rev 183:159-172.
17. Genain CP, Nguyen MH, Letvin NL, Pearl R, Davis RL, Adelman M, Lees MB, Linington C, Hauser SL. 1995. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest 96:2966-2974.
18. Gijbels K, Galardy RE, Steinman L. 1994. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 94:2177-2182.
19. Greco A, Minghetti L, Sette G, Fieschi C, Levi G. 1999. Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 53:1876-1879.
20. Grilli M, Memo M. 1999. Nuclear factor-kappaB/Rel proteins: a point of convergence of signalling pathways relevant in neuronal function and dysfunction. Biochem Pharmacol 57:1-7.
21. Ha HC, Snyder SH. 1999. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci USA 96:13978-13982.
22. Ha HC, Hester LD, Snyder SH. 2002. Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc Natl Acad Sci U S A 99:3270-3275.
23. Hafler DA. 2004. Multiple sclerosis. J Clin Invest 113:788-794.
24. Harlan JM, Winn RK. 2002. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit Care Med 30(Suppl 5):S214-S219.
25. Hilliard B, Samoilova EB, Liu TS, Rostami A, Chen Y. 1999. Experimental autoimmune encephalomyelitis in NF-kappa B-deficient mice: roles of NF-kappa B in the activation and differentiation of autoreactive T cells. J Immunol 163:2937-2943.
26. Homburg S, Visochek L, Moran N, Dantzer F, Priel E, Asculai E, Schwartz D, Rotter V, Dekel N, Cohen-Armon M. 2000. A fast signal-induced activation of Poly(ADP-ribose) polymerase: a novel downstream target of phospholipase c. J Cell Biol 150:293-307.
27. Huang CJ, Nazarian R, Lee J, Zhao PM, Espinosa-Jeffrey A, de Vellis J. 2002. Tumor necrosis factor modulates transcription of myelin basic protein gene through nuclear factor kappa B in a human oligodendroglioma cell line. Int J Dev Neurosci 20:289-296.
28. Izikson L, Klein RS, Luster AD, Weiner HL. 2002. Targeting monocyte recruitment in CNS autoimmune disease. Clin Immunol 103:125-131.
29. Kauppinen TM, Swanson RA. 2005. Poly(ADP-ribose) polymerase-1 promotes microglial activation, proliferation, and matrix metalloproteinase-9-mediated neuron death. J Immunol 174:2288-2296.
30. 2+, histones H(1) and H(3), and ATP. Biochemistry 43:210-216.
31. Lutton JD, Winston R, Rodman TC. 2004. Multiple sclerosis: etiological mechanisms and future directions. Exp Biol Med 229:12-20.
32. Maeda A, Sobel RA. 1996. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 55:300-309.
33. Malfroy B, Doctrow SR, Orr PL, Tocco G, Fedoseyeva EV, Benichou G. 1997. Prevention and suppression of autoimmune encephalomyelitis by EUK-8, a synthetic catalytic scavenger of oxygen-reactive metabolites. Cell Immunol 177:62-68.
34. Martino G, Adorini L, Rieckmann P, Hillert J, Kallmann B, Comi G, Filippi M. 2002. Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet 1:499-509.
35. Minagar A, Alexander JS. 2003. Blood-brain barrier disruption in multiple sclerosis. Mult Scler 9:540-549.
36. Nakajima H, Nagaso H, Kakui N, Ishikawa M, Hiranuma T, Hoshiko S. 2004. Critical role of the automodification of poly(ADP-ribose) polymerase-1 in the nuclear factor-kB-dependent gene expression in primary cultured mouse glial cells. J Biol Chem (in press).
37. Oliver FJ, Menissier-de Murcia J, Nacci C, Decker P, Andriantsitohaina R, Muller S, de la Rubia G, Stoclet JC, de Murcia G. 1999. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J 18:4446-4454.
38. Rieckmann P, Maurer M. 2002. Anti-inflammatory strategies to prevent axonal injury in multiple sclerosis. Curr Opin Neurol 15:361-370.
39. + depletion and ribosylation of 14-3-3gamma. J Neurochem 85:697-708.
40. Scott GS, Hake P, Kean RB, Virag L, Szabo C, Hooper DC. 2001. Role of poly(ADP-ribose) synthetase activation in the development of experimental allergic encephalomyelitis. J Neuroimmunol 117:78-86.
41. Scott GS, Kean RB, Mikheeva T, Fabis MJ, Mabley JG, Szabo C, Hooper DC. 2004. The therapeutic effects of PJ34 [N-(6-oxo-5, 6-dihydrophenanthridin-2-yl)- N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J Pharmacol Exp Ther 310:1053-1061.
42. Sharp C, Warren A, Oshima T, Williams L, Li JH, Alexander JS. 2001. Poly ADP ribose-polymerase inhibitors prevent the up-regulation of ICAM-1 and E-selectin in response to Th1 cytokine stimulation. Inflammation 25:157-163.
43. Suh SW, Aoyama K, Chen Y, Garnier P, Matsumori Y, Gum E, Liu J, Swanson RA. 2003. Hypoglycemic neuronal death and cognitive impairment are prevented by poly(ADP-ribose) polymerase inhibitors administered after hypoglycemia. J Neurosci 23:10681-10690.
44. Syburra C, Passi S. 1999. Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh 71:112-115.
45. Szabo C. 2002. PARP as a drug target for the therapy of diabetic cardiovascular dysfunction. Drug News Perspect 15:197-205.
46. Tokime T, Nozaki K, Sugino T, Kikuchi H, Hashimoto N, Ueda K. 1998. Enhanced poly(ADP-ribosyl)ation after focal ischemia in rat brain. J Cereb Blood Flow Metab 18:991-997.
47. Trapp BD, Bo L, Mork S, Chang A. 1999. Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 98:49-56.
48. Ullrich O, Diestel A, Eyupoglu IY, Nitsch R. 2001. Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1. Nat Cell Biol 3:1035-1042.
49. van der Valk P, De Groot CJ. 2000. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol Appl Neurobiol 26:2-10.
50. Vladimirova O, O'Connor J, Cahill A, Alder H, Butunoi C, Kalman B. 1998. Oxidative damage to DNA in plaques of MS brains. Mult Scler 4:413-418.
51. Vowinckel E, Reutens D, Becher B, Verge G, Evans A, Owens T, Antel JP. 1997. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res 50:345-353.
52. Wallstrom E, Diener P, Ljungdahl A, Khademi M, Nilsson CG, Olsson T. 1996. Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J Neurol Sci 137:89-96.
53. Wang ZQ, Auer B, Stingl L, Berghammer H, Haidacher D, Schweiger M, Wagner EF. 1995. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev 9:509-520.
54. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, Poirier GG, Dawson TM, Dawson VL. 2002. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297:259-263.